Optina Diagnostics
Changing mindsets when it comes to brain health
Changing mindsets when it comes to brain health
Optina Diagnostics is a biotechnology startup based in Canada that is revolutionizing medical diagnostics with its Retinal Deep Phenotyping platform. The company's goal is to improve the lives of older adults by enabling early-stage diagnosis of eye diseases and systemic diseases like Alzheimer's and cardiac stenosis.
Their FDA-cleared Optina-4C hyperspectral camera reveals unprecedented information about cellular and molecular changes in the retina, providing a new dimension to medical imaging. By combining data-rich images with Artificial intelligence-driven algorithms, Optina delivers automated and equitable diagnostic information.
Notably, Optina has received a Breakthrough Device Designation from the FDA for their Alzheimer's test, marking a significant advancement in the differential diagnosis of dementia.
In January 2022, Optina Diagnostics secured a $2.10M Venture Round investment led by the Alzheimer's Drug Discovery Foundation. The company's innovative approach to medical diagnostics and precision medicine positions it as a key player in the biotechnology industry, addressing critical challenges faced by healthcare systems supporting aging populations.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $2.10M | 1 | Alzheimer's Drug Discovery Foundation | 24 Jan 2022 |
| Series A | $24.80M | 7 |
|
28 Oct 2021 |
| Seed Round | Unknown | 2 |
|
12 Jun 2019 |
| Seed Round | $4.00M | - | 10 Oct 2018 | |
| Non Equity Assistance | Unknown | - | 01 Oct 2017 |
No recent news or press coverage available for Optina Diagnostics.
We care about your data, and we'd love to use cookies make your experience better.
